Browsing by Author "Painuly, D"

Now showing 1 - 6 of 6
  • Item
    Aqueous based Synthesis of CdSe/ZnS Q-dots: Study on Luminescence Properties and Cytotoxicity
    (PROCEEDING OF INTERNATIONAL CONFERENCE ON RECENT TRENDS IN APPLIED PHYSICS & MATERIAL SCIENCE (RAM 2013), 2013) Painuly, D; Bhatt, A; Krishnan, VK
    Present study aims to modify the thioacid capped CdSe Quantum-dots (Q-dots) surface by ZnS coating by direct synthesis in aqueous medium. CS formation was confirmed by red shift as well as enhancement in the luminescence peak compared to bare Q-dots. Effects of processing parameters during the shell preparation such as core concentration and sulphur concentration on the luminescence properties of CS have been studied. Processing parameters have been optimized at maximum luminescence efficiency. Cytocompatibility behavior was found to be better for CS compared to their bare Q-dots counterpart after evaluation. Cytotoxicity of CS has been further evaluated by changing the sulphur concentration and after aging for 8 days.
  • Item
    Cytocompatibility Evaluation of the Mercaptoethanol capped CdSe Quantum Dots and CdSe/ZnS Core/Shell
    (J Biomedical Nanotechnology, 2013-03) Painuly, D; Bhatt, A; Krishnan, VK
  • Item
    Mercaptoethanol Capped CdSe Quantum Dots and CdSe/ZnS Core/Shell: Synthesis, Characterization and Cytotoxicity Evaluation
    (JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2013) Painuly, D; Bhatt, A; Krishnan, VK
    CdSe Quantum dots (Q-dots) and CdSe/ZnS core/shell have been synthesized by wet chemical route using mercaptoethanol (ME) as cappant. The synthesized Q-dots and core/shell were characterized using X-ray diffraction (XRD), Transmission electron microscopy (TEM), Energy dispersive X-ray analysis (EDS), Dynamic Light Scattering (DLS), Optical absorption and luminescence spectroscopy. The core/shell formation was confirmed by both XRD and TEM analysis. The luminescence was shown to be considerably enhanced in the core/shell sample. Effect of dialysis process on the optical properties of the Q-dots and core/shell has also been discussed. Cytotoxicity studies have been carried out for Q-dots and core/shell. CdSe/ZnS core/shell was found to be non-cytotoxic as compared to CdSe Q-dots up to a certain concentration range. Polyethylene glycol (PEG) coating enhances the non-cytotoxic nature of CdSe/ZnS core/shell when compared with bare core/shell.
  • Item
    Physicochemical and invitro biocompatibility evaluation of water-soluble CdSe/ZnS core/shell
    (JOURNAL OF BIOMATERIALS APPLICATIONS, 2014) Painuly, D; Bhatt, A; Krishnan, VK
    Group II-VI semiconductor quantum dots (Q-dots) have found various applications in biomedical field during last decade. In this study, we have synthesized CdSe Q-dots and CdSe/ZnS core/shell (CS) by wet chemical route and characterized using X-ray diffraction (XRD), transmission electron microscopy (TEM), dynamic light scattering (DLS), Fourier-transform infrared spectroscopy (FT-IR) and Photoluminescence (PL) spectroscopy. CS formation was confirmed by red shift as well as enhancement in the luminescence peak compared to bare Q-dots. Processing parameters such as core and sulfur concentrations were optimized at maximum luminescence efficiency during the shell preparation. Effects of dialysis, aging and cell culture medium on the properties of the Q-dots and CS were also studied by luminescence and DLS techniques. DLS data showed Q-dots and CS to be stable, and there was no effect on the integrity of the Q-dots and CS after various modifications. CS was found to be hemocompatible and cytocompatible for human umbilical vein endothelial cells even at a high concentration of 0.1 mg/ml up to 48 h indicating high potential for CS in various biomedical applications.
  • Item
    Urokinase -CdSe/ZnS core/shell conjugates for targeted fibrinolytic treatment: An in vitro evaluation
    (Journal of Biomaterials & Tissue Engineering., 2014-10) Painuly, D; Bhatt, A; Krishnan, VK
    Cardiac diseases are one of the major causes of mortality worldwide. The conventional fibrinolytic therapy using drugs causes fibrinolysis in a non-specific and uncontrolled manner limiting the therapeutic potential of this therapy. If the drugs used can be specifically targeted and released in a controlled fashion at the site of the clot, a better therapeutic potential can be expected. In this study, we have monitored in vitro clot lysis generated by a quantum dot [Q-dot] based targeted drug delivery system. Urokinase, a plasminogen activator was conjugated with CdSe/ZnS core–shell (CS) by carbodimide coupling method to form urokinase-core/shell conjugate (UK-CS conjugate). These conjugates were characterized using X-ray diffraction (XRD), Dynamic Light Scattering (DLS), Fourier-Transform Infrared Spectroscopy (FT-IR), absorption and Photoluminescence (PL) spectroscopy. The optimum entrapment efficiency (E. E) was found to be ∼96% and the conjugate was found to be stable at 4 °C for 20 days of storage. The storage stability was determined in terms of size, absorbance and encapsulation efficiency. In vitro drug release studies exhibited controlled sustained release of UK from conjugate. In vitro thrombolysis testing on the plasma clot was carried out at different dose concentrations (18, 36 and 72 μg) of UK and UK-CS conjugate and the efficacy of UK-CS was found similar to bare UK at higher concentrations. Accelerated thrombolysis was observed in UK-CS-Ab system by binding the drug carrier specific to the clot using anti—fibrin antibody (Ab). Clot lysis time was found to decrease and comparable to UK even at 18 μg level compared to UK-CS conjugate. Thus, the proposed conjugate system based upon CS drug carriers may find potential use in therapeutic applications of thrombolytic diseases.
  • Item
    Urokinase-CdSe/ZnS Core/Shell Conjugates for Targeted Fibrinolytic Treatment: An In Vitro Evaluation
    (JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2014) Painuly, D; Bhatt, A; Krishnan, VK
    Cardiac diseases are one of the major causes of mortality worldwide. The conventional fibrinolytic therapy using drugs causes fibrinolysis in a non-specific and uncontrolled manner limiting the therapeutic potential of this therapy. If the drugs used can be specifically targeted and released in a controlled fashion at the site of the clot, a better therapeutic potential can be expected. In this study, we have monitored in vitro clot lysis generated by a quantum dot [Q-dot] based targeted drug delivery system. Urokinase, a plasminogen activator was conjugated with CdSe/ZnS core-shell (CS) by carbodimide coupling method to form urokinase-core/shell conjugate (UK-CS conjugate). These conjugates were characterized using X-ray diffraction (XRD), Dynamic Light Scattering (DLS), Fourier-Transform Infrared Spectroscopy (FT-IR), absorption and Photoluminescence (PL) spectroscopy. The optimum entrapment efficiency (E.E) was found to be similar to 96% and the conjugate was found to be stable at 4 degrees C for 20 days of storage. The storage stability was determined in terms of size, absorbance and encapsulation efficiency. In vitro drug release studies exhibited controlled sustained release of UK from conjugate. In vitro thrombolysis testing on the plasma clot was carried out at different dose concentrations (18, 36 and 72 mu g) of UK and UK-CS conjugate and the efficacy of UK-CS was found similar to bare UK at higher concentrations. Accelerated thrombolysis was observed in UK-CS-Ab system by binding the drug carrier specific to the clot using anti-fibrin antibody (Ab). Clot lysis time was found to decrease and comparable to UK even at 18 mu g level compared to UK-CS conjugate. Thus, the proposed conjugate system based upon CS drug carriers may find potential use in therapeutic applications of thrombolytic diseases.